[go: up one dir, main page]

TN2011000227A1 - Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy - Google Patents

Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy

Info

Publication number
TN2011000227A1
TN2011000227A1 TN2011000227A TN2011000227A TN2011000227A1 TN 2011000227 A1 TN2011000227 A1 TN 2011000227A1 TN 2011000227 A TN2011000227 A TN 2011000227A TN 2011000227 A TN2011000227 A TN 2011000227A TN 2011000227 A1 TN2011000227 A1 TN 2011000227A1
Authority
TN
Tunisia
Prior art keywords
salt
treating
dabigatran etexilate
over conventional
improved efficacy
Prior art date
Application number
TN2011000227A
Other languages
English (en)
Inventor
Paul A Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41463075&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000227(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TN2011000227A1 publication Critical patent/TN2011000227A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TN2011000227A 2008-11-11 2011-05-10 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy TN2011000227A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11341308P 2008-11-11 2008-11-11
US23755909P 2009-08-27 2009-08-27
PCT/EP2009/064874 WO2010055022A1 (fr) 2008-11-11 2009-11-10 Procédé de traitement ou de prévention de thrombose à l'aide d'étexilate de dabigatran ou d'un sel de celui-ci avec une efficacité accrue par rapport à une thérapie classique par warfarine

Publications (1)

Publication Number Publication Date
TN2011000227A1 true TN2011000227A1 (en) 2012-12-17

Family

ID=41463075

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000227A TN2011000227A1 (en) 2008-11-11 2011-05-10 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy

Country Status (21)

Country Link
US (3) US20110269799A1 (fr)
EP (1) EP2355823A1 (fr)
JP (1) JP2013510073A (fr)
KR (1) KR20110082564A (fr)
CN (2) CN103463083A (fr)
AR (1) AR074107A1 (fr)
AU (1) AU2009315730A1 (fr)
BR (1) BRPI0921354A2 (fr)
CA (1) CA2738884A1 (fr)
CL (1) CL2011000806A1 (fr)
CO (1) CO6382133A2 (fr)
EA (1) EA201100755A1 (fr)
EC (1) ECSP11011029A (fr)
IL (1) IL211853A0 (fr)
MA (1) MA32785B1 (fr)
MX (1) MX2011004796A (fr)
NZ (1) NZ592615A (fr)
PE (1) PE20110432A1 (fr)
TN (1) TN2011000227A1 (fr)
TW (1) TW201031651A (fr)
WO (1) WO2010055022A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358368A1 (fr) 2008-11-11 2011-08-24 Boehringer Ingelheim International GmbH Procede de traitement et de prevention de la thrombose utilisant l'etexilate de dabigatran ou un sel de celui-ci avec un profil de securite ameliore par rapport a la therapie de la warfarine classique
EP2550966B1 (fr) * 2011-07-25 2016-10-19 Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG Esters d'acide carboxylique d'amidoxime du dabigatran en tant que prodrogues et leur utilisation comme médicament
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
WO2015071841A1 (fr) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes de dabigatran et ses dérivés, procédé de préparation de ceux-ci et compositions pharmaceutiques contenant ceux-ci
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
CN108254216B (zh) * 2018-03-15 2021-04-27 攀钢集团西昌钢钒有限公司 一种高炉槽的矿料取样方法、装置及可读存储介质
WO2020180489A1 (fr) * 2019-03-06 2020-09-10 University Of Rochester Compositions anticoagulantes et utilisations associées

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555581B1 (en) * 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
MX2009000602A (es) * 2006-07-17 2009-01-28 Boehringer Ingelheim Int Nuevas indicaciones para los inhibidores directos de la trombina en el campo cardiovascular.

Also Published As

Publication number Publication date
NZ592615A (en) 2013-06-28
PE20110432A1 (es) 2011-07-16
JP2013510073A (ja) 2013-03-21
BRPI0921354A2 (pt) 2019-09-24
TW201031651A (en) 2010-09-01
CO6382133A2 (es) 2012-02-15
MX2011004796A (es) 2011-05-30
US20110269799A1 (en) 2011-11-03
EP2355823A1 (fr) 2011-08-17
WO2010055022A1 (fr) 2010-05-20
ECSP11011029A (es) 2011-06-30
CN103463083A (zh) 2013-12-25
EA201100755A1 (ru) 2011-12-30
AU2009315730A1 (en) 2010-05-20
US20120277269A1 (en) 2012-11-01
CN102209546A (zh) 2011-10-05
AR074107A1 (es) 2010-12-22
CL2011000806A1 (es) 2011-11-11
US20100322870A1 (en) 2010-12-23
MA32785B1 (fr) 2011-11-01
IL211853A0 (en) 2011-06-30
CA2738884A1 (fr) 2010-05-20
KR20110082564A (ko) 2011-07-19

Similar Documents

Publication Publication Date Title
TN2011000227A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
NZ592616A (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA200970933A1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
IL189546A0 (en) Therapy for the treatment of disease
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
WO2010044585A3 (fr) Composes de piperidine, composition pharmaceutique les contenant et utilisation associee
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
WO2009114089A3 (fr) Utilisation de fullerenes pour augmenter et stimuler la croissance capillaire
ECSP13012847A (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación.
NZ592613A (en) Method for treating or preventing thrombosis using >150 mg to 300 mg b.i.d. of dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
AU2009246603A8 (en) Von willebrand factor (vwf) inhibitors for treatment or prevention of infarction
WO2007022408A3 (fr) Methodes de traitement du cancer combinant saha et targretin
WO2009155070A3 (fr) Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques
MX348723B (es) Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
UA105645C2 (uk) Застосування етексилату дабігатрану, необов'язково у формі фармацевтично прийнятної солі, для запобігання інсульту у пацієнта, що страждає від миготливої аритмії
UA104158C2 (ru) Профилактика инсульта у пациента, который страдает мигающей аритмией, с использованием этексилата дабигатрана
WO2008016665A3 (fr) Composés et méthodes de traitement de troubles médiés par flt3
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
WO2011156900A3 (fr) Composés, compositions et procédés pour traiter la sclérose en plaques
MX2007002532A (es) Metodos para el tratamiento de enfermedades proliferativas de la piel utilizando derivados de carbazol.
WO2007054725A3 (fr) Produit compose
WO2006042277A3 (fr) Compositions a liberation prolongee d'inhibiteurs de pompes a protons
WO2013177478A3 (fr) Méthode de traitement